Weight change and hormonal contraception: fact and fiction

References

• Wellings K, Zhihong Z, Krentel A, Barrett G, Glasier A. Attitudes towards long-acting reversible methods of contraception in general practice in the UK. Contraception76, 208–214 (2007).
   PubMed Web of Science ®Google Scholar
• Vaughan B, Trussell J, Kosy K, Singh S, Jones R. Discontinuation and resumption of contraceptive use: results from the 2002 National Survey of Family growth. Contraception78, 271–283 (2008).
   PubMed Web of Science ®Google Scholar
• World Health Organization Special Programme of Research, Development and Research Training in Human Reproduction. Task Force on Long-Acting Systemic Agents for the Regulation of Fertility. Multinational comparative clinical evaluation of two long-acting injectable contraceptive steroids: norethisterone enanthate given in two dosage regimens and depot medroxyprogesterone acetate: final report. Contraception23, 1–20 (1983).
   Google Scholar
• Said S, Omar K, Koetsawang S et al. A multicentred Phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100 mg or 150 mg: 1. Contraceptive efficacy and side effects. World Health Organization Task Force on Long-Acting Systemic Agents for Fertility Regulation. Special Programme of Research, Development and Research Training in Human Reproduction. Contraception34(3), 223–235 (1986).
   PubMed Web of Science ®Google Scholar
• Harel Z, Biro FM, Kollar LM, Rauh JL. Adolescents reasons for and experience after discontinuation of the long-acting contraceptive Depo-Provera and Norplant. J. Adolesc. Health19, 118–123 (1996).
   PubMed Web of Science ®Google Scholar
• Emans J, Grace E, Woods ER. Adolescents compliance with the use of oral contraceptives. J. Am. Med. Assoc.257, 3377–3381 (1987).
   PubMed Web of Science ®Google Scholar
• Hamani Y, Sciaki-Tamir Y, Deri-Hasid R, Miller-Pogrund T, Milwidsky A, Haimov-Kochman R. Misconceptions about oral contraception pills among adolescents and physicians. Hum. Reprod.22, 3078–3083 (2007).
   PubMed Web of Science ®Google Scholar
• Venkat P, Masch R, Ng E, Cremer M, Richman S, Arslan A. Knowledge and beliefs about contraception in urban Latina women. J. Community Health33, 357–362 (2008).
   PubMed Web of Science ®Google Scholar
• Rosenburg MJ, Waugh MS. Oral contraceptive discontinuation: a prospective evaluation of frequency and reasons. Am. J. Obstet. Gynecol.179, 577–582 (1998).
   PubMedGoogle Scholar
• Paul C, Skegg DCG, Williams S. Depo-medroxyprogesterone acetate: patterns of use and reasons for discontinuation. Contraception56, 209–214 (1997).
   PubMed Web of Science ®Google Scholar
• Turner R. Most British women use reliable contraceptive methods, but many fear health risks from use. Fam. Plan. Persp.26, 183–184 (1994).
   Google Scholar
• Karlsson R, Linden A, Von Schultz B. Supression of 24 hour cholecystokinen secretion by oral contraceptives. Am. J. Obstet. Gynecol.167, 58–59 (1992).
   PubMed Web of Science ®Google Scholar
• Amatayakul K, Sivasomboon B, Thanangkul O. A study of the mechanism of weight gain in medroxyprogesterone acetate users. Contraception22, 605–622 (1980).
   PubMed Web of Science ®Google Scholar
• Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM. Combination contraceptives: effects on weight. Cochrane Database Syst. Rev.4, CD003987 (2008).
   Google Scholar
• Bahamondes L, Del Castillo S, Tabares G, Arce XE, Perrotti M, Petta C. Comparison of weight increase in users of depot medroxyprogesterone acetate and copper IUD up to 5 years. Contraception64, 223–225 (2001).
   PubMed Web of Science ®Google Scholar
• Espey E, Steinhart J, Ogburn T, Qualls C. Depo-Provera associated with weight gain in Navajo women. Contraception62, 55–58 (2000).
   PubMed Web of Science ®Google Scholar
• Clark MK, Dillon JS, Sowers M, Nichols S. Weight, fat mass, and central distribution of fat increase when woman use depot-medroxyprogesterone acetate for contraception. Int. J. Obes.29, 1252–1258 (2005).
   PubMed Web of Science ®Google Scholar
• Berenson MD, Rahman M. Changes in weight, total fat, percent boy fat, and central-to-peripheral fat ratio associated with injectable and oral contraceptive use. Am. J. Obstet. Gynecol.200(93), 329.el–e8 (2009).
   Google Scholar
• Mainwaring R, Hales HA, Stevenson K et al. Metabolic parameters, bleeding, and weight changes in US women using progestin-only contraceptives. Contraception51, 149–153 (1995).
   PubMed Web of Science ®Google Scholar
• Le YL, Rahman M, Berenson AB. Early weight gain predicting later weight gain among depot medroxyprogesterone acetate users. Obstet. Gynecol.114, 279–284 (2009).
   PubMed Web of Science ®Google Scholar
• Leiman G. Depo-medroxyprogesterone acetate as a contraceptive agent: its effect on weight and blood pressure. Am. J. Obstet. Gynecol.114, 97–102 (1972).
   PubMed Web of Science ®Google Scholar
• Pantoja M, Medeiros T, Baccarin MC, Morais SS, Bahamondes L, dos Santos Fernandes AM. Variations in body mass index of users of depot-medroxyprogesterone acetate as a contraceptive. Contraception81, 107–111 (2010).
   PubMed Web of Science ®Google Scholar
• Rissir WL, Gefter LR, Barratt MS, Risser JM. Weight change in adolescents who used hormonal contraception. J. Adolesc. Health24, 433–436 (1999).
   PubMedGoogle Scholar
• Matson SC, Henderson KA, McGrath GJ. Physical findings and symptoms of depot medroxyprogesterone acetate use in adolescent females. J. Pediatr. Adolesc. Gynecol.10, 18–23 (1997).
   PubMedGoogle Scholar
• Bonny A, Britto M, Huang B, Succop P, Slap GB. Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J. Pediatr. Adolesc. Gynecol.17, 109–115 (2004).
   PubMedGoogle Scholar
• Bonny AE, Ziegler J, Harvey R, Debanne S, Cromer BA. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone acetate, oral contraceptive pills, or no hormonal contraceptive method. Arch. Pediatr. Adolesc. Med.160, 40–45 (2006).
   PubMed Web of Science ®Google Scholar
• Mangan SA, Larsen PG, Hudson S. Overweight teens at increased risk for weight gain while using depot medroxyprogesterone acetate. J. Pediatr. Adolesc. Gynecol.15, 79–82 (2002).
   PubMedGoogle Scholar
• Beksinska ME, Kleinschmidt I, Smit JA, Milford C, Farley TMM. Prospective study of weight change in new adolescent users of DMPA, NET-EN, COCs, non users and discontinuers of contraception. Contraception81(1), 30–34 (2010).
   PubMed Web of Science ®Google Scholar
• Moore LL, Valuck R, McDougall C, Fink W. A comparative study of one-year weight gain among users of medroxyprogesterone acetate, levonorgestrel implants, and oral contraceptives. Contraception52, 215–219 (1995).
   PubMed Web of Science ®Google Scholar
• Taneepanichskul S, Reinprayoon D, Khaosaad P. Comparative study of weight change between long-term DMPA and IUD acceptors. Contraception58, 149–151 (1998).
   Web of Science ®Google Scholar
• Taneepanichskul S, Reinprayoon D, Jaisamrarn U. Effects of DMPA on weight and blood pressure in long term acceptors. Contraception58, 149–151 (1998).
   Web of Science ®Google Scholar
• El Mahgoub S. Body weight and cycle control of injectable contraceptives. J. Reprod. Med.24, 119–126 (1980).
   PubMedGoogle Scholar
• Gallo MF, Grimes DA, Schulz KF, Helmerhorst FM. Combination estrogen–progestin contraceptives and body weight: systematic review of randomized controlled trials. Obstet. Gynecol.103, 359–373 (2004).
   PubMed Web of Science ®Google Scholar
• Rosenberg M. Weight changes with COC use and during the menstrual cycle. Contraception58, 345–349 (1998).
   PubMed Web of Science ®Google Scholar
• Coney P, Wasenik K, Langley RGB, Di Giovanna JJ, Harrison DD. Weight change and adverse event incidence with a low-dose oral contraceptive: two randomized, placebo-controlled trials. Contraception63, 297–302 (2001).
   PubMed Web of Science ®Google Scholar
• Goldzeiher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil. Steril.22, 609–623 (1971).
   PubMedGoogle Scholar
• Gupta S. Weight gain on the combined pill – is it real? Hum. Reprod. Update6, 427–431 (2000).
   PubMed Web of Science ®Google Scholar
• Hatcher RA, Trussell J, Nelson AL, Cates W, Stewart FH, Kowal D. Contraceptive Technology (19th revised edition). Ardent Media, NY, USA (2007).
   Google Scholar
• World Health Organization Department of Reproductive Health and research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communications Programs (CCP), INFO Project. Family Planning: a Global Handbook for Providers. CCP and WHO, Baltimore (MD, USA) and Geneva (Switzerland) (2007).
   Google Scholar
• Westoff CF, Ryder NB. Duration of use of oral contraception in the United States, 1960–1965. Public Health Rep.83(4), 277–287 (1968).
   PubMed Web of Science ®Google Scholar
• Bagshaw S. The combined oral contraceptive. Risks and adverse effects in perspective. Drug Saf.12(2), 91–96 (1995).
   PubMed Web of Science ®Google Scholar
• Carpenter S, Neinstein LS. Weight gain in adolescent young adult COC users. J. Adolesc. Health Care7(5), 342–344 (1986).
   PubMedGoogle Scholar
• Neel EU, Litt IF, Jay MS. Side effects and compliance with low-and conventional-dose oral contraceptives among adolescents. J. Adolesc. Health Care8(4), 327–329 (1987).
   PubMedGoogle Scholar
• Khoo SK, Hacker N, Chang A. An incremental-dose combined oestrogen–progestogen oral contraceptive: effects on body weight, blood pressure, and biochemical parameters. Aust. N. Z. J. Obstet. Gynecol.20(3), 172–176 (1980).
   PubMedGoogle Scholar
• Reubinoff BE, Grubstein A, Meirow D, Berry E, Schenker JG, Brzezinski A. Effects of low-dose estrogen oral contraceptives on weight, body composition, and fat distribution in young women. Fertil. Steril.63(3), 516–521 (1995).
   PubMed Web of Science ®Google Scholar
• Rapkin AJ. Yaz in the treatment of premenstrual dysphoric disorder. J. Reprod. Med.53(9 Suppl.), 729–741 (2008).
   PubMed Web of Science ®Google Scholar
• Milsom I, Lete I, Bjertnaes A et al. Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 µg ethinyl estradiol and 3 mg drospirenone. Hum. Reprod.21, 2304–2311 (2006).
   PubMed Web of Science ®Google Scholar
• Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G. A comparative assessment of ORTHO EVRA TM/EVRA TM to placebo patch effects on body weight. Fertil. Steril.76(Suppl. 1), 188 (2001).
   Google Scholar
• Stewart FH, Kaunitz AM, La Guardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet. Gynecol.105, 1389–1396 (2005).
   PubMed Web of Science ®Google Scholar
• Sibai B, Odlind V, Meador M, Shangold G, Fisher A, Creasy G. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (ORTHO Evra/Evra). Fertil. Steril.77(Suppl. 2), S19–S26 (2002).
   PubMed Web of Science ®Google Scholar
• Harel Z, Riggs S, Vaz R, Flanagan P, Dunn K, Harel D. Adolescents’experience with the combined estrogen and progesting transdermal contraceptive method. Ortho Evra. J. Pediatr. Adolesc. Gynecol.18(2), 85–90 (2005).
   PubMedGoogle Scholar
• Miller L, Verhoeven CHJ, Hout J. Extended regimens of the contraceptive vaginal ring. Obstet. Gynecol.3, 473–482 (2005).
   Google Scholar
• Novak A, de la Loge C, Abetz L, van der Meulen EA. The combined contraceptive vaginal ring, Nuva Ring®: an international study of user acceptability. Contraception67, 187–194 (2003).
   PubMed Web of Science ®Google Scholar
• Roumen F, Apter D, Mulders T, Dieben T. Efficacy, tolerability and acceptability of a novel contraceptive vaginal ring releasing etonogestrel and ethinyl oestradiol. Hum. Reprod.16, 469–475 (2001).
   PubMed Web of Science ®Google Scholar
• O’Connell KJ, Osborne LM, Westhoff C. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive. Contraception72(5), 323–327 (2005).
   PubMed Web of Science ®Google Scholar
• Barreiros FA, Guazzelli CAF, Barbosa R, de Assis F, de Araujo FF. Extended regimens of the contraceptive vaginal ring: evaluation of clinical aspects. Contraception81, 223–225 (2010).
   PubMed Web of Science ®Google Scholar
• Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet. Gynecol.100, 585–593 (2002).
   PubMed Web of Science ®Google Scholar
• Bahamondes L, Diaz J, Petta C, Hall P. Weight variation in users of the once-a-month injectable contraceptive Cyclofem. Adv. Contraception14(4), 185–192 (1998).
   PubMedGoogle Scholar
• Hassan EO, el-nahal N, el-Hussinie M. Once-a-month injectable contraceptives, Cyclofem and Mesigyna, in Egypt. Efficacy, causes of discontinuation, and side effects. Contraception60(2), 87–92 (1999).
   PubMed Web of Science ®Google Scholar
• Davis AJ. Use of depot medroxyprogesterone acetate contraception in adolescents. J. Reprod. Med.41(5), 407–413 (1996).
   PubMedGoogle Scholar
• Margulies R, Miller L. Increased depot medroxyprogesterone acetate use increases family planning program pharmaceutical supply costs. Contraception63(3), 147–149 (2001).
   PubMedGoogle Scholar
• Jain J, Jakimiuk AJ, Bode FR, Ross D, Kaunitz AM. Contraceptive efficacy and safety of DMPA-SC. Contraception70, 269–275 (2004).
   PubMed Web of Science ®Google Scholar
• Westhoff C, Jain JK, Milsom I et al. Changes in weight with depot medroxyprogesterone acetate subcutaneous injection 104 mg/0.65 ml. Contraception75, 261–267 (2007).
   PubMed Web of Science ®Google Scholar
• Chaudhri R, Rizvi F, Afzal M. Body weight and bleeding pattern changes in woman using DMPA-SC. J. Coll. Physicians Surg. Pak.19, 618–621 (2009).
   PubMedGoogle Scholar
• Curtis KM, Ravi A, Gaffield ML. Progestogen-only contraceptive use in obese women. Contraception80, 346–354 (2009).
   PubMed Web of Science ®Google Scholar
• Howard G, Blair M, Fotherby K, Elder MG, Bye P. Seven years clinical experience of the injectable contraceptive, norethisterone oenanthate. Br. J. Fam. Plann.11, 9–16 (1985).
   Google Scholar
• Glasier A. Implantable contraceptives for women: effectiveness, discontinuation rates, return of fertility, and outcome of pregnancies. Contraception65, 29–37 (2002).
   PubMed Web of Science ®Google Scholar
• Glantz S, Glantz JC, Campbell-Heider N, Schaff E. Norplant use among urban minority women in the United States. Contraception61(2), 83–90 (2000).
   PubMedGoogle Scholar
• Sivin I, Alvarez F, Mishell DR et al. Contraception with two levenorgestrel rod implants: a 5-year study in the United States. Contraception58, 275–282 (1998).
   PubMed Web of Science ®Google Scholar
• Berenson AB, Weimann CM, Rickens V. Contraceptive outcomes among adolescents prescribed Norplant implants vs COC after one year of use. Am. J. Obstet. Gynecol.176, 586–592 (1997).
   PubMed Web of Science ®Google Scholar
• Kozlowski KJ, Rickert VI, Hendon A, Davis P. Adolescents and Norplant: preliminary findings of side effects. J. Adolesc. Health.16, 373–378 (1995).
   PubMedGoogle Scholar
• Darney P, Patel A, Rosen K, Shapiro LS, Kaunitz AM. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international trials. Fertil. Steril.91(5), 1646–1653 (2009).
   PubMed Web of Science ®Google Scholar
• Croxatto H, Urbancsek J, Massai R, Bennink HC, van Beek A; Implanon study group. A multicenter efficacy and safety study of the single contraceptive implant Implanon®. Hum. Reprod.14(4), 976–981 (1999).
   PubMed Web of Science ®Google Scholar
• Funk S, Miller MM, Mishell DR et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception71(5), 319–326 (2005).
   PubMed Web of Science ®Google Scholar
• No authors listed. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 micrograms/day or levonorgestrel 30 micrograms/day. Collaborative study group on the desogestrel-containing progestogen-only pill. Eur. J. Contracept. Reprod. Health Care3(4), 169–178 (1998).
   PubMedGoogle Scholar
• Yela DA, Monterio IM, Bahamondes LG, del Castillo S, Bahamondes MV, Fernandes A. Weight variation in users of the levonorgesterel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil. Rev. Assoc. Med. Bras.52(1), 32–36 (2006).
   PubMedGoogle Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999–2008. JAMA303(3), 235–241 (2010).
   PubMed Web of Science ®Google Scholar
• Yost J, Krainovich-Miller B, Budin W, Norman R. Assessing weight perception accuracy to promote weight loss among U.S female adolescents: a secondary analysis. BMC Public Health10, 465 (2010).
   PubMedGoogle Scholar
• Wane S, van Uffelen JGZ, Brown W. Determinants of weight gain in young women. J. Women’s Health19(7), 1327–1340 (2010).
   PubMed Web of Science ®Google Scholar
• Janssen I, Katzmarzzyk PT, Boyce WF et al. Comparison of overweight and obesity prevalence in school-aged youth from 34 countries and their relationship with physical activity. Obesity Rev.2, 123–132 (2005).
   Google Scholar